Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)

研究成果: Comment/debate同行評審

指紋

深入研究「Correction to: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study (BMC Pulmonary Medicine, (2021), 21, 1, (165), 10.1186/s12890-021-01530-6)」主題。共同形成了獨特的指紋。

Medicine & Life Sciences